IDEAYA Biosciences Inc. has announced its financial results for the second quarter ended June 30, 2025. The company reported cash, cash equivalents, and marketable securities totaling approximately $991.9 million, down from $1.05 billion as of March 31, 2025. This decrease was mainly attributed to net cash used in operations. Research and development expenses for the quarter were $74.2 million, an increase from $70.9 million in the previous quarter. The rise was due to higher clinical trial expenses and personnel-related costs. General and administrative expenses also increased to $14.6 million from $13.5 million, driven primarily by higher personnel-related expenses. IDEAYA anticipates that its current cash position will fund operations into 2029. The company is continuing to scale its organization in preparation for the potential U.S. launch of darovasertib, including strategic hires in commercial, medical affairs, and market access functions. In terms of clinical developments, IDEAYA is on track with its Phase 2/3 trial of the darovasertib and crizotinib combination in 1L HLA-A2-negative metastatic uveal melanoma, with median progression-free survival data expected by year-end 2025. Additionally, median overall survival data from a Phase 2 trial involving the same combination will be shared in the fourth quarter of 2025, along with Phase 2 data from a study on darovasertib in primary uveal melanoma patients to be presented at the European Society of Medical Oncology conference.